An observational study in Multiple Sclerosis, Relapsing-Remitting and Healthy Controls, sponsored by Centre d'Investigation Clinique et Technologique 805. Recruiting at 1 site in France. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-06.
Sponsored by Centre d'Investigation Clinique et Technologique 805 · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France — 9 open to participants now, 14 under way, 7 of them phase 3. Multiple Sclerosis, Relapsing-Remitting · France.
Among the 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France, this one is the 11th largest by planned enrollment of the 12 observational ones that give a count, is one of 3 that started in 2022, is one of 12 observational ones, reaches primary completion later than 0 of the 13 other live ones, and was the 72nd registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →9 of the 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France are open now. Recruiting first, the newest first:
University Hospital, Montpellier · Sites in France
Ages 40+
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18–55
Rennes University Hospital · Sites in France
Ages 18–55
University Hospital, Strasbourg, France · Sites in France
Ages 18–55 · Men only
University Hospital, Strasbourg, France · Sites in France
Ages 18–70
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is below the median of 120 across 157 observational studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 154 across the 70 interventional studies, 499 across the 12 observational. Of the 65 that completed or were terminated, 28 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 82 have an industry lead sponsor. The 10 most frequent:
Centre d'Investigation Clinique et Technologique 805 is the lead sponsor of 75 studies on the registry; 2 are open to participants now.
Centre d'Investigation Clinique et Technologique 805 has 1 study filed under Multiple Sclerosis, Relapsing-Remitting — fewer than ten, so there is no comparison to draw.
6 of the studies in Multiple Sclerosis, Relapsing-Remitting with a site in France that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06663189Phase 3University Hospital, Strasbourg, FranceDisease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis) | 2027-01 |
| NCT06700343Phase 3AmgenComparison Between ABP 692 and Ocrevus® (Ocrelizumab) | 2027-04-19 |
| NCT03958877Phase 3BiogenA Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis | 2027-05-20 |
| NCT05519553Nantes University HospitalPeer Support Impact on Therapeutic Adherence in Patients With Multiple Sclerosis | 2026-12-01 |
| NCT06330077Assistance Publique - Hôpitaux de ParisIfenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis | 2027-03 |
Add all 6 to your calendar (.ics) → With an account.
Among the 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Personal identity is composed of multiple facets of the self that are constructed and nourished through memories of past experiences (i.e., autobiographical memory) and the imagination of events that may occur in the future (i.e., future thinking) .
While our previous work has shown that people with relapsing-remitting multiple sclerosis (pwRRMS) have autobiographical memory and future thought disorders, their impact on personal identity has not yet been explored. Based on a cognitive and clinical neuropsychology approach, this research project aims to better understand the cognitive mechanisms involved in the relationship between identity, autobiographical memory and future thinking in pwRRMS. We will examine the extent to which pwRRMS manage to maintain and reshape their identity through life experiences, with a particular interest in the potential integration of the disease as a facet of their identity. In addition, we will explore the positive and/or negative consequences of disease-related identity changes on emotional well-being and quality of life, as well as their links with the duration and severity of the disease. Overall, this research project will contribute to identify new therapeutic levers that can be used for the development of adapted and personalized care.
Primary care clinic
For the clinical group:
Inclusion Criteria:
Non-inclusion Criteria:
For the control group:
Inclusion Criteria:
Non-inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
45 individuals with relapsing-remitting multiple sclerosis
Behavioral: Neuropsychological tests and psychological questionnaires
45 individuals with no chronic disease, matched in age, gender and level of education
Behavioral: Neuropsychological tests and psychological questionnaires
* The clinical group will complete: * the BCcogSEP: a comprehensive neuropsychological examination * the IAM and I WILL BE tasks; experimental neuropsychological tasks to assess autobiographical memory, future thinking and personal identity * A series of questionnaires including the BRIEF COPE, the Connor Davidson Resilience Scale, the Satisfaction with Life Scale and the Hospital Anxiety and Depression Scale, which respectively assess coping strategies, resilience, life satisfaction and anxiety/depression * The control group will complete: * the IAM and I WILL BE tasks; experimental neuropsychological tasks to assess autobiographical memory, future thinking and personal identity * A series of questionnaires including the BRIEF COPE, the Connor Davidson Resilience Scale, the Satisfaction with Life Scale and the Hospital Anxiety and Depression Scale, which respectively assess coping strategies, resilience, life satisfaction and anxiety/depression
Relationships between personal identity, autobiographical memory and future thinking
Scores obtained at the I AM and I WILL BE tasks assessing the access, qualitative properties of self-concepts, episodic richness and temporal organization of past and future events around self-concepts (between-group comparisons, pwRRMS versus control group)
Time frame: 15 days
Relationships between personal identity, psychological functioning and clinical characteristics
Correlations between IAM and I WILL BE scores and scores obtained at the different questionnaires (BRIEF COPE, Connor Davidson Resilience Scale, Satisfaction with Life Scale, Hospital Anxiety and Depression Scale) Correlations between IAM and I WILL BE scores and level of functional disability (Expanded Disability Status Scale) Correlations between IAM and I WILL BE scores and disease duration
Time frame: 15 days
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2022 (actual). Primary completion is estimated for Dec 2024, 24 months after the start.
Of 42 non-industry observational studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 56. This study's planned 24 months is below that.
Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 22 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Multiple Sclerosis, Relapsing-Remitting →
Centre d'Investigation Clinique et Technologique 805